WO2008071081A1 - 低出血抗凝血融合蛋白的制备及其应用 - Google Patents
低出血抗凝血融合蛋白的制备及其应用 Download PDFInfo
- Publication number
- WO2008071081A1 WO2008071081A1 PCT/CN2007/003526 CN2007003526W WO2008071081A1 WO 2008071081 A1 WO2008071081 A1 WO 2008071081A1 CN 2007003526 W CN2007003526 W CN 2007003526W WO 2008071081 A1 WO2008071081 A1 WO 2008071081A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- recognized
- coagulation factor
- cleaved
- oligopeptide
- anticoagulant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6443—Coagulation factor XIa (3.4.21.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21027—Coagulation factor XIa (3.4.21.27)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention belongs to the field of biotechnology and relates to a structure and a preparation method of a low-bleeding anticoagulant substance and its use in the prevention and treatment of thrombotic diseases and thrombosis-related diseases.
- the present invention relates to a novel substance in which an anticoagulant substance is linked to an amino acid sequence which can be recognized and cleaved by several blood coagulation factors including thrombin, factor Xa (FXa), factor XIa (FXIa), and the like. , and the preparation and medicinal uses of these new substances.
- Background technique is relates to a novel substance in which an anticoagulant substance is linked to an amino acid sequence which can be recognized and cleaved by several blood coagulation factors including thrombin, factor Xa (FXa), factor XIa (FXIa), and the like.
- Cardiovascular and cerebrovascular diseases are the number one killers that threaten human health and life in recent years. Thrombosis is an important cause of many cardiovascular and cerebrovascular diseases. Anticoagulants are important drugs for preventing and treating thrombosis. The currently widely used anticoagulant is mainly heparin. An important disadvantage of heparin is thrombocytopenia (thrombocytopenia). The development of low molecular weight heparin now reduces the risk of heparin application, but does not overcome its shortcomings. Hirudin is a new anticoagulant that has been marketed in Europe in recent years.
- thrombin It is a direct inhibitor of thrombin, but its strong inhibitory effect on thrombin can lead to blood coagulation related parameters such as bleeding time, APTX, TT and PT. It rises sharply and is associated with a risk of systemic or systemic bleeding.
- the key to the guiding principle of the present invention is to conditionally release the anticoagulant activity of the anticoagulant, that is, under normal conditions, the substance has no anticoagulant activity.
- the coagulation system When the coagulation system is activated, there is a possibility of thrombosis or thrombosis, the anticoagulant activity of the substance is released locally, creating an environment in which thrombus is not easily formed (ie, local anticoagulant activity occurs) to prevent thrombosis. Or the existing thrombus continues to grow, even dissolve the tiny emboli that has formed to achieve the function of preventing thrombosis. This overcomes the risk of systemic bleeding caused by anticoagulants such as heparin and hirudin.
- hirudin is a single-chain polypeptide consisting of 65 to 66 amino acids. Its amino terminus can bind to the catalytic active site of thrombin and has anticoagulant activity. The carboxy terminus binds to the substrate recognition site of thrombin and has a strong specific affinity for thrombin.
- a method for blocking the amino terminus of hirudin was designed to temporarily block the anticoagulant activity of hirudin.
- the characteristics of the biochemical changes induced by the thrombus are used to restore the amino terminal blocked hirudin to the hirudin form, and to play a specific part in the thrombus that may or may have occurred. It is a new type of safe, effective anticoagulant that reduces the risk of systemic bleeding caused by hirudin.
- the hirudin has been modified. Because the laboratory has been identified on the amino terminus of hirudin by an oligopeptide that can be recognized and cleaved by thrombin (the hirudin derivative is named TH) or the oligopeptide recognized and cleaved by coagulation factor Xa (the hirudin derivative is named It is FH) so that once the coagulation system is activated, the anticoagulant activity of hirudin is released, which acts as an anticoagulant and antithrombotic agent and reduces bleeding side effects. The results show that it has a certain effect, but the effect is still poor.
- oligopeptides that can be recognized and lysed by several coagulation factors or other coagulation factors. It is hoped that the effect can be improved and the practical application can be achieved.
- these oligopeptides can be efficiently recognized and cleaved by the corresponding coagulation factors when thrombosis occurs, and it is not currently speculated according to the relevant literature.
- the laboratory has prepared two related proteins: 1 The oligopeptide of the hirudin is recognized and cleaved by thrombin and factor Xa, respectively.
- the hirudin derivative is named GH; 2
- the oligopeptide of the hirudin is linked to an oligopeptide which is recognized and cleaved by coagulation factor XI a and coagulation factor Xa, respectively, and the hirudin derivative is named EH.
- the results showed that the two hirudin derivatives did not have anticoagulant activity under normal conditions in vitro and in vivo. Once the in vivo coagulation system was activated, the anticoagulant activity of hirudin could be efficiently released under the combined action of the above coagulation factors. , anticoagulant and antithrombotic effects.
- An object of the present invention is to provide a substance which does not have anticoagulant activity itself, and which can locally release its anticoagulant activity in the presence of a thrombus when thrombus occurs or thrombus occurs, thereby preventing thrombosis.
- the present inventors have now discovered that the sequence identified by coagulation factor XIa and coagulation factor Xa, or the sequence recognized by thrombin and coagulation factor Xa, respectively, can be linked to an anticoagulant substance to achieve closure of the anticoagulant activity of the anticoagulant substance, and Cleavage under certain conditions.
- the derived anticoagulant substance has the following characteristics:
- the anticoagulant substance such as the base end of hirudin is blocked by the sequence recognized by the above two coagulation factors, and has no anticoagulant activity in vitro and non-thrombus sites of the blood system, thereby avoiding or It reduces the side effects of systemic hemorrhage caused by anticoagulant substances such as hirudin; the derived anticoagulant is only required to release free anticoagulation only when thrombus occurs, under the action of the specific blood coagulation factor at the thrombus site.
- the physical shield plays a role in the prevention and treatment of blood clots, so the side effects of systemic bleeding are significantly reduced.
- the sequence recognized by the two coagulation factors respectively blocks the amino terminus of an anticoagulant substance such as hirudin, which can be cleaved by two coagulation factors in the body, and the effect is much better than the recognition sequence of a single coagulation factor.
- Anticoagulant For example, the amino terminus of hirudin is blocked.
- the first aspect of the present invention relates to an anticoagulant substance comprising an oligopeptide which is co-recognized and cleaved by coagulation factor XIa and coagulation factor Xa or an oligopeptide which is co-recognized and cleaved by thrombin and coagulation factor Xa.
- a further aspect of the present invention relates to a method for producing an anticoagulant comprising an oligopeptide which is co-recognized and lysed by coagulation factor XIa and coagulation factor Xa or which is co-identified and cleaved by coagulation factor Xa, comprising a factor XIa
- the nucleotide sequence corresponding to the co-recognition sequence of coagulation factor Xa or the sequence recognized by thrombin and coagulation factor Xa is linked to the anticoagulant protein gene, and these genes are then constructed into vectors suitable for expression, such as pBV220, pPIC9, pPIC91. [Sequence, these recombinant vectors containing the gene of interest are expressed in a suitable host, for example, in E. coli, yeast or animal cell systems to give new anticoagulant substances.
- a further aspect of the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising the above novel anticoagulant and a pharmaceutically acceptable carrier or excipient.
- anticoagulant substance or "anticoagulant substance” means a substance capable of anticoagulation, such as hirudin, antithrombin I II, snake venom, or the like, or a mutant thereof. Or other substance having anticoagulant action, preferably hirudin or a mutant thereof.
- the oligopeptide which is recognized by the factor Xa refers to the tripeptide sequence EPR (GluProArg) or the peptide containing the EPR, or the pentapeptide sequence GVYAR (GlyValTyrAlaArg) or the peptide containing GVYAR.
- the anticoagulant substance of the present invention comprising an oligopeptide which is co-recognized and cleaved by coagulation factor XIa and coagulation factor Xa or which is co-identified and cleaved by coagulation factor Xa is preferably attached to the amino terminal of hirudin. EPR or GVYAR.
- the anticoagulant substance of the present invention comprising an oligopeptide which is co-recognized and cleaved by coagulation factor XIa and coagulation factor Xa or which is co-identified and cleaved by coagulation factor Xa can be expressed in a suitable host system. Preferably expressed in E. coli or yeast.
- Figure 1 shows the nucleotide sequences of EH and GH.
- Figure 2 shows the amino acid sequences of EH and GH.
- EH EPR-HV2
- GH GVYAR-HV2
- the restriction enzyme cleavage site Xho I and the coagulation factor XIa and the coagulation factor Xa co-recognition sequence EPR or the base sequence corresponding to the co-recognition sequence GVTAR of the coagulation factor Xa are introduced into the upstream of the hirudin (HV2) gene by PCR.
- the EcoR I restriction site was introduced downstream of the HV2 gene, and the gene was ligated to the same digested PPIC9 plasmid to obtain recombinant plasmids pPIC9-EH and pPIC9-GH.
- PIC9-EH and PPIC9-GH and pPIC9K were double-digested with BamH I and Sal I to obtain PPIC9K-EH and PPIC9K-GH.
- Two recombinant plasmids were electrotransformed into the yeast genome and induced to express using methanol. The expressed product was isolated and purified to obtain the target proteins EH and GH.
- GH, EH, FH and TH were cleaved with thrombin, FXa and FXIa, respectively, and the anticoagulant activity of the product was determined by fibrin clot method after lysis. The results are shown in Table 1.
- Table 1 Analysis of anticoagulant activity of GH, EH, FH and TH before and after cleavage by thrombin, FXa and FXIa
- FXIa 0 0 0 0 0 0 0 0 0 0 64 0 256 512
- Table 1 GH can be recognized and cleaved by two clotting factors, thrombin and FXa, respectively.
- EH can be recognized and lysed by FXa and FXIa clotting factors, respectively.
- ⁇ ⁇
- FH is only recognized and cleaved by FXa
- TH is only recognized and cleaved by thrombin.
- EH, GH, FH and TH can prolong the time of common carotid artery thrombosis in rats, and dose-dependent, indicating that these hirudin derivatives have anti-arterial Thrombosis function, and the effect is basically similar to each other, but it is very different in terms of bleeding side effects.
- Table 3 and Table 4 that GH, EH, FH and TH have less influence on bleeding index than HV2. It shows that it is safer than HV2; and GH and EH have much less impact on the bleeding index than FH and TH, especially the bleeding time of GH is significantly lower than that of FH and TH group, indicating that GH and EH are reduced.
- the side effects of bleeding are significantly better than FH or TH.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT07845883T ATE533789T1 (de) | 2006-12-15 | 2007-12-11 | Herstellung von mit geringen blutungen assoziiertem gerinnungshemmendem fusionsprotein und dessen verwendung |
US12/519,309 US8101379B2 (en) | 2006-12-15 | 2007-12-11 | Preparation of low bleeding anticoagulant fusion protein and its use |
CN2007800463406A CN101668778B (zh) | 2006-12-15 | 2007-12-11 | 低出血抗凝血融合蛋白的制备及其应用 |
EP07845883A EP2103630B1 (en) | 2006-12-15 | 2007-12-11 | Preparation of low bleeding anticoagulant fusion protein and its use |
JP2009540580A JP5345069B2 (ja) | 2006-12-15 | 2007-12-11 | 低出血性抗凝固性融合タンパク質の調製および使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610165756.7 | 2006-12-15 | ||
CN200610165756 | 2006-12-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008071081A1 true WO2008071081A1 (zh) | 2008-06-19 |
WO2008071081A8 WO2008071081A8 (zh) | 2009-08-13 |
Family
ID=39511252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2007/003526 WO2008071081A1 (zh) | 2006-12-15 | 2007-12-11 | 低出血抗凝血融合蛋白的制备及其应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8101379B2 (zh) |
EP (1) | EP2103630B1 (zh) |
JP (1) | JP5345069B2 (zh) |
CN (1) | CN101668778B (zh) |
AT (1) | ATE533789T1 (zh) |
WO (1) | WO2008071081A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115572329A (zh) * | 2021-06-21 | 2023-01-06 | 王大勇 | 一组活性增强代谢较慢的菲牛蛭基因重组水蛭素及其制备方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1737889E (pt) | 2004-10-19 | 2010-12-13 | Lonza Ag | Método para síntese de péptidos em fase sólida |
CN102180973B (zh) * | 2011-03-18 | 2012-08-29 | 重庆大学 | 靶向多功能防栓融合蛋白及其制备方法和应用 |
CN109206522B (zh) * | 2017-07-07 | 2021-11-09 | 北京三有利和泽生物科技有限公司 | 一种长效抗凝血融合蛋白及其应用 |
CN113956339B (zh) * | 2021-10-28 | 2023-02-24 | 中国药科大学 | 宽体金线蛭抗凝血因子XIa多肽及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1896108A (zh) * | 2005-06-01 | 2007-01-17 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 特异性抗凝血物质的制备及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759542A (en) * | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
DK0833848T3 (da) * | 1995-06-12 | 2001-11-05 | Sanquin Bloedvoorziening | Faktor IX-bindende peptider afledt af faktor VIII og anvendelse heraf som inhibitorer af blodkoagulation |
US5910481A (en) * | 1995-11-13 | 1999-06-08 | Immuno Ag | Hybrid proteins with modified activity |
CN1480466A (zh) * | 2002-09-03 | 2004-03-10 | �й������ž�����ҽѧ��ѧԺ����ҽ | 一类溶栓抗凝双功能融合蛋白及应用 |
-
2007
- 2007-12-11 AT AT07845883T patent/ATE533789T1/de active
- 2007-12-11 CN CN2007800463406A patent/CN101668778B/zh active Active
- 2007-12-11 WO PCT/CN2007/003526 patent/WO2008071081A1/zh active Application Filing
- 2007-12-11 EP EP07845883A patent/EP2103630B1/en active Active
- 2007-12-11 US US12/519,309 patent/US8101379B2/en active Active
- 2007-12-11 JP JP2009540580A patent/JP5345069B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1896108A (zh) * | 2005-06-01 | 2007-01-17 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 特异性抗凝血物质的制备及其应用 |
Non-Patent Citations (3)
Title |
---|
JENNY R.J.A.: "Critical Review of the Methods for Cleavage of Fusion Proteins with Thrombin and Factor Xa", PROTEIN EXPRESSION AND PURIFICATION, vol. 31, no. 1, 2003, pages 1 - 11, XP004454310 * |
NIU J.Y. ET AL.: "Design and Functional Investigation of a Novel Anti-coagulative Fusion Protein by Hirudin With a Recognizing Sequence of FXa", CHINA BIOTECHNOLOGY, vol. 26, no. 4, April 2006 (2006-04-01), pages 36 - 39, XP008108976 * |
SAPORITO-IRWIN S.M.: "Coagulation Factor XIa Cleaves the RHDS Sequence and Abolishes the Cell Adhesive Properties of the Amyloid beta-Protein", J. BIOL. CHEM., vol. 270, no. 44, 3 November 1995 (1995-11-03), pages 26265 - 26269, XP008108901 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115572329A (zh) * | 2021-06-21 | 2023-01-06 | 王大勇 | 一组活性增强代谢较慢的菲牛蛭基因重组水蛭素及其制备方法 |
CN115572329B (zh) * | 2021-06-21 | 2024-02-06 | 王大勇 | 一组活性增强代谢较慢的菲牛蛭基因重组水蛭素及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2008071081A8 (zh) | 2009-08-13 |
JP5345069B2 (ja) | 2013-11-20 |
US8101379B2 (en) | 2012-01-24 |
JP2010512349A (ja) | 2010-04-22 |
EP2103630B1 (en) | 2011-11-16 |
EP2103630A4 (en) | 2010-07-28 |
US20100234291A2 (en) | 2010-09-16 |
US20100113345A1 (en) | 2010-05-06 |
CN101668778A (zh) | 2010-03-10 |
EP2103630A1 (en) | 2009-09-23 |
ATE533789T1 (de) | 2011-12-15 |
CN101668778B (zh) | 2012-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cunningham et al. | Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis | |
KR101884954B1 (ko) | 지혈 작용을 가진 조직인자를 함유하는 인지질이 풍부한 소포 및 그의 용도 | |
Zhu et al. | The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer | |
JP2008509688A (ja) | 改変ビタミンk依存性ポリペプチド | |
JPS61205487A (ja) | ヒトプロティンc活性の発現ベクター | |
WO2008071081A1 (zh) | 低出血抗凝血融合蛋白的制备及其应用 | |
WO1995016460A1 (fr) | Dispositif a semi-conducteur | |
EP3593861B1 (en) | Combination of car peptide and a vasodilator for treating pulmonary hypertension | |
JP2010184930A (ja) | 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 | |
WO2015100768A1 (zh) | 聚乙二醇化的组织激肽释放酶及其制备方法和应用 | |
CN103974716A (zh) | 凝血因子Ⅶ和Ⅶa衍生物、包括其的缀合物和复合体及其用途 | |
CN101190945A (zh) | 特异性抗凝血物质的制备及其应用 | |
WO2013131406A1 (zh) | 解聚海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 | |
EP3227326A1 (en) | Recombinant clusterin and use thereof in the treatment and prevention of disease | |
EP0458903A1 (en) | Soluble analogs of thrombomodulin | |
CN1896108B (zh) | 特异性抗凝血物质的制备及其应用 | |
CN103044554B (zh) | 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用 | |
JPH10510271A (ja) | ジスルフィド−シクロ−[H−Cys−Glu−Gln−Tyr−Cys−OH]および血液凝固障害におけるその用途 | |
WO2008046256A1 (fr) | Hemocoagulase | |
CN102443065A (zh) | 特异性抗凝血物质的制备及其应用 | |
US10837007B2 (en) | Recombinant fusion proteins for preventing or treating adhesions of tissues or organs | |
CN114081965B (zh) | 一种外泌体递送载体及其制备方法、应用 | |
CN103626850A (zh) | 具有细胞穿透功能的多肽及其在药物递送中的用途 | |
JP4256497B2 (ja) | 血管炎治療剤 | |
CN104628868B (zh) | 重组二聚化抗凝血酶III-Fc融合蛋白及其哺乳动物细胞高效表达系统 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780046340.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07845883 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009540580 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007845883 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12519309 Country of ref document: US |